The FDA has updated the indication and usage section of the Dapagliflozin (Farxiga) label, effective 2026-04-06. This significant revision specifies that dapagliflozin tablets are now indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus who also have either established cardiovascular disease or multiple cardiovascular risk factors.
Background
Dapagliflozin, marketed as Farxiga, is an SGLT2 inhibitor, a class of drugs primarily used to improve glycemic control in adults with type 2 diabetes mellitus. Beyond its glucose-lowering effects, SGLT2 inhibitors have demonstrated cardiovascular and renal benefits in various clinical trials. This label update reflects the growing understanding of dapagliflozin's broader protective effects, specifically addressing heart failure risk in a high-risk population with type 2 diabetes.
What this means
This label update provides clinicians with clearer, official guidance on the use of dapagliflozin for a specific, vulnerable patient population. It formally recognizes the drug's proven benefit in reducing the risk of hospitalization for heart failure among adults with type 2 diabetes mellitus who have either established cardiovascular disease or multiple cardiovascular risk factors. This expanded indication allows healthcare providers to proactively leverage dapagliflozin for its established cardiorenal protective effects in these at-risk patients, moving beyond its traditional role solely as a glucose-lowering agent. The update reinforces the importance of considering comprehensive patient profiles, including cardiovascular risk, when managing type 2 diabetes.
Source
The information regarding this label revision was directly sourced from the FDA. The updated indication and usage for Dapagliflozin became effective on 2026-04-06, as detailed in the official label document available on dailymed.nlm.nih.gov.